Raltegravir
NO SIGNIFICANT CHANGES IN WEIGHT AND BODY FAT MASS IN SUPPRESSED HIV-INFECTED PATIENTS SWITCHED TO DUAL COMBINATION LAMIVUDINE PLUS DOLUTEGRAVIR OR RALTEGRAVIR.